8-K Announcements
6Material company update
May 5, 2026·SEC
Material company update
Apr 6, 2026·SEC
Material company update
Apr 2, 2026·SEC
Minerva Neurosciences, Inc.(NERV)Earnings, Financials & Key Ratios
NERV•NASDAQ
$5.15
Price updated Jul 2, 2026
AboutMinerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone for the treatment of schizophrenia; and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders. Minerva Neurosciences, Inc. has a license agreement with Mitsubishi Tanabe Pharma Corporation to develop, sell, and import roluperidone globally excluding Asia. The company was formerly known as Cyrenaic Pharmaceuticals, Inc. and changed its name to Minerva Neurosciences, Inc. in 2013. Minerva Neurosciences, Inc. was incorporated in 2007 and is headquartered in Waltham, Massachusetts.Show more
- Revenue$0
- EBITDA-$15M+30.8%
- Net Income-$293M-20492.7%
- EPS (Diluted)-34.67-18347.4%
NERV Price & Volume
Minerva Neurosciences, Inc. (NERV) stock price & volume — 10-year historical chart
Loading chart...
Regulatory Setbacks Drive Severe Capital Erosion Risks
Investment Thesis • Updated 2026Q1
VerdictNegative
Growth:Contracting
Profitability:Negative
Financial:Vulnerable
Cash Flow:Burning
Primary Risk:Regulatory binary outcome risk
Key Thesis Takeaways
- Minerva Neurosciences faces a precarious outlook as the lack of recurring revenue and the receipt of a Complete Response Letter for its lead asset, roluperidone, create significant binary outcome risks.
- The company's reliance on external financing is evidenced by a surge in total debt to $65.0 million in 2026Q1, while R&D expenditures of $5.3 billion continue to outpace operational capacity.
- Investors should remain cautious as the current cash runway of $32.8 million appears insufficient to support the additional clinical trials likely required for regulatory approval.
Verdict Logic
the company's precarious financial position is underscored by a negative $254.0 million equity base and a significant reliance on external debt to fund operations.
NERV Growth Metrics
Minerva Neurosciences, Inc. (NERV) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-28947.36%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-15447.37%
Return on Capital
10 Years-38.72%
5 Years-45.19%
3 Years-38.69%
Last Year-23.24%
NERV Recent Earnings
Minerva Neurosciences, Inc. (NERV) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 5/12 qtrs (42%)
Q2 2026Latest
May 5, 2026Metric
Actual
Est
EPS
$0.17-30.8%
$0.13
Rev
—
—
Q2 2026
Mar 11, 2026Metric
Actual
Est
EPS
$0.64-481.8%
$0.11
Rev
—
—
Q4 2025
Nov 5, 2025Metric
Actual
Est
EPS
$0.36-2.9%
$0.35
Rev
—
—
Q3 2025
Aug 14, 2025Metric
Actual
Est
EPS
$0.43+54.7%
$0.95
Rev
—
—
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 5, 2026 | $0.17vs $0.13-30.8% | — |
| Q2 2026 | Mar 11, 2026 | $0.64vs $0.11-481.8% | — |
| Q4 2025 | Nov 5, 2025 | $0.36vs $0.35-2.9% | — |
| Q3 2025 | Aug 14, 2025 | $0.43vs $0.95+54.7% | — |
Based on last 12 quarters of dataView full earnings history →
Peers Comparison
Key metrics vs top competitors for Minerva Neurosciences, Inc. (NERV)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $5.15 | $36.01M | -0.15 | — | — | — | — | |
| $25.20 | $4.31B | 11.00 | 11.87% | 34.3% | 35.65% | — | |
| $21.90 | $1.62B | 6.64 | 18.52% | 118.91% | 47.59% | — | |
| $240.66 | $12.38B | -65.40 | 65.55% | -26.59% | -260.01% | — | |
| $5.98 | $462.21M | 37.38 | -4.9% | 3.16% | 12.53% | — | |
| $3.86 | $66.72M | -2.88 | — | -1070.26% | — | — |
Compare NERV vs Peers
Minerva Neurosciences, Inc. (NERV) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
NERV SEC Filings & Documents
Minerva Neurosciences, Inc. (NERV) SEC filings — annual & quarterly reports (10-K, 10-Q)
Get notified when NERV posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
NERV Frequently Asked Questions
Minerva Neurosciences, Inc. (NERV) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Is NERV profitable?
Minerva Neurosciences, Inc. (NERV) reported a net loss of $415.1M for fiscal year 2025.
Dividend & Returns
What is Minerva Neurosciences, Inc.'s free cash flow?
Minerva Neurosciences, Inc. (NERV) had negative free cash flow of $5.44B in fiscal year 2025, likely due to heavy capital investments.